During the last session, Roivant Sciences Ltd. (NASDAQ:ROIV)’s traded shares were 1.03 million. At the end of the trading day, the stock’s price was $2.81, reflecting an intraday loss of -0.35% or -$0.01. The 52-week high for the ROIV share is $16.76, that puts it down -496.44 from that peak though still a striking 1.42% gain since the share price plummeted to a 52-week low of $2.77. The company’s market capitalization is $2.04B, and the average intraday trading volume over the past 10 days was 0.33 million shares, and the average trade volume was 412.72K shares over the past three months.
Roivant Sciences Ltd. (ROIV) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. ROIV has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.24.
Roivant Sciences Ltd. (NASDAQ:ROIV) trade information
Roivant Sciences Ltd. (ROIV) registered a -0.35% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.35% in intraday trading to $2.81 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -26.05%, and it has moved by -29.40% in 30 days. Based on these gigs, the overall price performance for the year is -71.56%. The short interest in Roivant Sciences Ltd. (NASDAQ:ROIV) is 2.93 million shares and it means that shorts have 9.81 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.33, which implies an increase of 80.39% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11.00 and $16.00 respectively. As a result, ROIV is trading at a discount of -469.4% off the target high and -291.46% off the low.
Revenue for the current quarter is expected to be $8.89 million as predicted by 5 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $7.64 million by the end of Mar 2022.
While earnings are projected to return -35.50% in 2022.
Roivant Sciences Ltd. is due to release its next quarterly earnings on November 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Roivant Sciences Ltd. (NASDAQ:ROIV)’s Major holders
Roivant Sciences Ltd. insiders own 39.32% of total outstanding shares while institutional holders control 49.15%, with the float percentage being 81.01%. QVT Financial LP is the largest shareholder of the company, while 46 institutions own stock in it. As of Dec 30, 2021, the company held over 129.39 million shares (or 18.70% of all shares), a total value of $1.3 billion in shares.
The next largest institutional holding, with 99.38 million shares, is of SB Investment Advisers (UK) LTD’s that is approximately 14.36% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $1.0 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Roivant Sciences Ltd. (ROIV) shares are iShares NASDAQ Biotechnology ETF and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that iShares NASDAQ Biotechnology ETF owns about 2.65 million shares. This amounts to just over 0.38 percent of the company’s overall shares, with a $26.75 million market value. The same data shows that the other fund manager holds slightly less at 0.98 million, or about 0.14% of the stock, which is worth about $9.92 million.